1. AD is a group of diseases which have similar neurological symptoms, thus AD can be grouped into different subtypes.
2. Age is the most significant risk factor of AD, and aging impairs the immune system.
3. The majority of AD cases can be defined as being an immunological disease (Immunesenescence) with neurological symptoms.
Moreover, Everyone is susceptible to AD because the immune system declines with age.
Soluble Aβ are digested by enzymes and bound by proteins, leading to good immunity. However binding to ApoE4 leads to impaired immunity due to a lack of protein production.
Neuronal stress leads to the over-expression of Tau and p-Tau. Consequently, insoluble Aβ lead to microglia-induced inflammation in the central nervous system, as well as inflammation in the peripheral immune system. This, along with the neuronal stress leads to Alzheimer’s Disease
Alzheimer’s Disease Treatment Prerequisites
In order to create an effective and safe treatment for Alzheimer’s Disease, it is crucial to target at least one of the major pathological proteins, such as Aβ or Tau. Then, it is necessary to rehabilitate the impaired immune system by balancing the acquired and innate immune systems. This is done with the objective of causing no harm to the patient undergoing the long-term treatment. Nonetheless, it is also necessary to avoid repeated treatments when possible
Principles Used to Treat Alzheimer’s Disease Patients
We have designed a novel vaccine with immunomodulatory efffects and multiple other functions by using concepts from traditional Chinese medicine, specifically Jun-Chen-Zhou-Shi